NICE stands for The National Institute for Health and Care Excellence and is responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health
NICE is an independent organisation. It was set up in 1999 to evaluate medications, treatments and procedures and decide whether they should be available on the NHS in England and Wales. It is important to remember that Scotland and Northern Ireland have separate organisations to make these decisions.
NICE presents its recommendations through Clinical Guidelines (CGs) and through Technical Appraisals (TAs), which evaluate efficacy and cost-effectiveness of treatments and medications.
What are 'pathways'? Click here for more information
NICE quality standards
NICE quality standards are a concise set of prioritised statements designed to drive measurable quality improvements within a particular area of health or care. They are derived from high quality guidance such as that from NICE or other sources accredited by NICE.
Quality standards are developed independently by NICE, in collaboration with healthcare professionals and public health and social care practitioners, their partners and service users. Information on priority areas, people's experience of using services, safety issues, equality and cost impact are also considered during the development process.
NICE quality standards enable:
• Health professionals and public health and social care practitioners to make decisions about care based on the latest evidence and best practice.
• People receiving health and social care services, their families and carers and the public to find information about the quality of services and care they should expect from their health and social care provider.
• Service providers to quickly and easily examine the performance of their organisation and assess improvement in standards of care they provide.
• Commissioners to be confident that the services they are purchasing are high quality and cost effective and focussed on driving up quality.
Read more about NICE
Keep updated on guidance in development: NICE E-bull
NICE News updates and UK Guidelines
November 2014: Update on Bradycardia (without atrioventricular block) - dual chamber pacemakers
NICE Question Time – Coventry
Public Q&A with NICE’s Chief Executive and Chair
Wednesday 19 November 2014, University Hospitals Coventry and Warwickshire NHS Trust.
Are you interested in finding out how NICE could help improve the health and wellbeing of people in Coventry and the surrounding area? Would you like the chance to put questions to NICE’s Chief Executive, Chairman and senior staff directly? Then book your place today.
NICE Question Time – Coventry is a unique event, open to all members of the public and the community and voluntary sector and we would be delighted if you could join us. It will take place between 12:30pm and 1:30pm, with an informal networking lunch beforehand at 12 noon.
For more information, or to register to attend NICE Question Time – Coventry and the NICE Public Board Meeting, please visit www.nice.org.uk/coventry2014. Please note, registration requires a NICE account; this is a free account and should only take a couple of minutes to activate.
November 2014: NICE value the contribution that members of the public make to their guidance and quality standards.
If you would like to consider becoming a representative, please view the current opportunities.
October 2014: NICE issues correction for anticoagulant and antidepressant drug interaction recommendations
Specifically, a correction was made to the table of drug interactions in Appendix 16, page 366. For conditions requiring anticoagulation, mirtazapine has been moved from the ‘Antidepressants to avoid or use with caution’ column to the ‘Antidepressants recommended’ column.
24 September 2014: Nice issues guidance on self-monitoring for people on long-term warfarin therapy
The National Institute for Health and Care Excellence releases diagnostics guidance on two new devices to support self-testing for NHS use.
June 2014: NICE publish update on AF management: CG180
NICE issued new guidelines on the care and treatment for AF in June 2014 - the first since 2006. What does this mean for your AF care and management?
Learn about changes to the role of anticoagulation, symptom control and shared decision making:
Visit AF Association's Care AF website - individualised care
NICE Implementation Collaborative: Consensus: Supporting local implementation of NICE guidance on use of the novel (non-Vitamin K antagonist) oral anticoagulants in non-valvular atrial fibrillation.
AF Association welcomes NICE clinical guideline on management of AF
15 June 2014, Sky News
Charity Founder and CEO, Trudie Lobban MBE, backs new guidelines that will assess the role of aspirin in the management of AF-related stroke. Watch now
Patient choice in anticoagulation
Warfarin has been trusted for decades, and is an effective medication for preventing AF-related stroke. Warfarin inhibits (delays) the clotting process, and does this by acting on chemicals produced by vitamin K in our blood. People on warfarin need to have regular blood tests to ensure that the warfarin dose to maintain the target INR level (the capacity for the blood to clot) is correct.
Dabigatran was approved by NICE in 2012 for use in the UK. It differs from warfarin because the way it delays the clotting process is not dependent on levels of vitamin K in the body. For this reason it is called a non-vitamin K antagonist. It is also known as a direct thrombin inhibitor (thrombin is an enzyme which promotes blood clotting). Dabigatran is about as effective as warfarin (if not slightly more) as an AF-related stroke preventive measure. What does NICE say?
Rivaroxaban is a non-vitamin K antagonist. The dosage is convenient – it is a tablet taken once a day with meals. As with all anticoagulants, it can cause internal bleeding. Rivaroxaban has fewer drug interactions compared with warfarin and there are none of the concerns for moderating the vitamin K intake in the diet. What does NICE say?
Apixaban was approved by NICE for use in the UK in January 2013. Like dabigatran, it is taken as a twice daily tablet and does not require frequent blood monitoring, and so it may be more convenient if your lifestyle involves frequent travel. Trials have suggested that with apixaban there are fewer bleeds in the brain than with warfarin. What does NICE say?
April 2014 social care update